Nitrome Biosciences Raises $38M Series A Financing to Advance Therapeutics Targeting a Novel Group of Enzymes involved in Age-related Diseases
Nitrome Biosciences Raises $38M Series A Financing to Advance Therapeutics Targeting a Novel Group of Enzymes involved in Age-related Diseases
04/22/20, 1:05 PM
Location
san franciscoMoney raised
$38 million
Round Type
series a
Nitrome Biosciences (Nitrome), a privately-held biopharmaceutical company developing a platform around a newly identified class of enzymes to target Parkinson’s disease and other age-related disorders, today announced that it has closed a Series A financing of $38 million co-led by Sofinnova Partners, a leading European life sciences venture capital firm, and AbbVie Ventures, AbbVie’s corporate strategic venture capital arm, with further participation from the Dementia Discovery Fund, Mission Bay Capital and Alexandria Venture Investments. Henrijette Richter, Ph.D., Managing Partner of Sofinnova Partners, Margarita Chavez, Managing Director of AbbVie Ventures and Jonathan Behr, Ph.D., Partner of the Dementia Discovery Fund, will join Nitrome’s Board of Directors.
Company Info
Location
san francisco, california, united states
Additional Info
Nitrome Biosciences is a platform company developing drugs against a newly identified class of enzymes called Nitrases, initially targeting Parkinson’s disease. The therapies that Nitrome is developing will target these enzymes and potentially help slow or halt the progression of diseases such as Parkinson’s. While the initial focus is on Parkinson's disease, the company aims to expand its proprietary platform to include other disease indications. Nitrome has been widely recognized, and has won multiple awards including the prestigious Target Advancement grant from The Michael J. Fox Foundation for Parkinson's Research (MJFF). For more information, please visit our website at www.nitromebiosciences.com.